EM3 Methodology specializes in MDI and DPI Technology
Em3 Methodology is not a cannabis company. We do not sell cannabis inhalers.
Em3 Methodology provides turn key aerosol systems to licensed cannabis manufactures that wish to ad the cannabis inhaler to their product line. We provide aerosol equipment, supplies,training, specific formulations, aerodynamic particle size testing and total dose testing to our customers.
We utilize a NGI for our particle size classification and a Agilent 1100 HPLC for our chromatography analysis. Our customers get the added benefit of this equipment as we test ALL of our customers products to ensure maximum effectiveness.
The MDI was not designed to be an oral mouth ( swallowed ) or sub-lingual spray. The MDI, if manufactured correctly, the MDI delivers API to the deep lung where it can be absorbed directly into the systemic blood stream for delivery directly to the brain without passing thru the liver first, about 95% bioavailability.
In order to get the API to travel into the deep lung, several components of the MDI and the formulation have to developed in a very specif manner. After a formula is created for taste and mg/A is decided, the formula has to be dispensed thru numerous sized actuators to determine which actuator has the best nozzle and jet length for that specif formula.
To do this Em3 has created a mobile lab that consists of NGI and HPLC analytical equipment that can measure the exact aerodynamic particle size of the API so that the correct actuator can be ordered from the suppliers.
Our equipment and testing can provide the cannabis manufactures with the MMAD and GSD figures as proof the API has been developed and the correct actuator has been selected for their product. Our lab is mobile and all testing is done on the licensed facility grounds.
Em3’s method is so highly refined, we are able to formulate 100% homogeneous formulas that do not require the end user to shake the inhaler before use!